| 08:30 | | Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes | Oscar MIRO (Barcelona, Spain) |
|
| 08:40 | 20 | Discussion - Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. | Mitja LAINSCAK (Murska Sobota, SI) |
|
| 08:43 | | Acute heart failure congestion and perfusion status; impact of the clinical classification on in hospital and long term outcomes; insights from the ESC EORP HFA Heart Failure Long Term Registry | Ovidiu CHIONCEL (Bucuresti, Romania) |
|
| 08:53 | 21 | Discussion - Acute heart failure congestion and perfusion status; impact of the clinical classification on in hospital and long term outcomes; insights from the ESC EORP HFA Heart Failure Long Term Registry. | Mandeep MEHRA (Boston, US) |
|
| 08:56 | | Effective and safe decongestion using the Reprieve-System in patients with acute heart failure: the results of the TARGET-1 and TARGET-2 studies | Pawel SIWOLOWSKI (Wroclaw, Poland) |
|
| 09:06 | 22 | Discussion -TARGET-1 and TARGET-2. | Andrew COATS (Coventry, GB) |
|
| 09:09 | | Activity of the Adrenomedullin system to personalize post-discharge treatment in acute heart failure | Nikola KOZHUHAROV (Basel, Switzerland) |
|
| 09:19 | 23 | Discussion - Activity of the Adrenomedullin system to personalize post-discharge treatment in acute heart failure. | Alan MAISEL (Solana Beach, US) |
|
| 09:22 | | Safety and Efficacy of 24-hour Istaroxime Infusion in Patients Hospitalized for Acute Decompensated Heart Failure | Marco METRA (Brescia, Italy) |
|
| 09:32 | 24 | Discussion - Safety and Efficacy of 24-hour Istaroxime Infusion in Patients Hospitalized for Acute Decompensated Heart Failure.. | Joann LINDENFELD (Nashville, US) |
|
| 09:35 | | Lung Ultrasound Guided Treatment in Ambulatory Patients with Heart Failure: a Randomized Controlled Clinical Trial (LUS-HF study) | Mercedes RIVAS LASARTE (Barcelona, Spain) |
|
| 09:45 | 25 | LUS-HF study - Discussion. | Peter PANG (Indianapolis, US) |
|
| 09:48 | | Panel Discussion. | |
|